Apr 12, 2022 / 05:30PM GMT
Gil Blum - Needham & Company, LLC - Analyst
Good afternoon, and welcome to day 2 of the annual Needham & Company healthcare conference. My name is Gil Blum, and I am a senior biotech analyst here at Needham & Company, covering the immuno-oncology and gene therapy subsectors. It is my pleasure to have with me today Julian Adams from Gamida Cell. (Conference Instructions)
And with that, Julian, you have the stage.
Julian Adams - Gamida Cell Ltd. - CEO
Thank you, Gil, and thank you to all joining us this morning on the call -- or this afternoon, I guess. There is a few forward-looking statements to go through, and you could consult our 10-K filing recently to describe more detail.
So Gamida Cell has been long committed to cellular therapy. And I'll give you an executive summary and then go through the programs. But we have very near-term promise and also long-term potential.
On the far left, omidubicel is our cell therapy to treat patients requiring hematopoietic stem cell transplant and has the potential to be the first
Gamida Cell Ltd at Needham Healthcare Conference Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers